Abt-263

Lymphoma

AbbottPhase 1Dormant

CC

44/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 37/ 100
Competitive Position: 65/ 100

Competitive context

289 Active assets in the Lymphoma cohort.

Asset / Sponsor	Phase	Rating
VINBLASTINE Intensity Therapeutics, Inc.	Phase 4	BBB
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE The Lymphoma Academic Research Organisation	Phase 4	BBB
BLEOMYCIN Shandong Provincial Hospital	Phase 4	BB
VINCRISTINE SULFATE Inhye Ahn	Phase 3	BB
(+)-VINCRISTINE Beth Israel Deaconess Medical Center	Phase 4	BB

View all 50 →

Same molecule, other indications

Abt-263 is also rated in:

B-cell chronic lymphocytic leukemiaDormant

BB

Indicative ·

70 / 100

chronic lymphocytic leukemia/small lymphocytic lymphomaDormant

B

Indicative ·

62 / 100

lymphoid neoplasmDormant

B

Indicative ·

60 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.